关注
Byron DeLaBarre
Byron DeLaBarre
The Consulting Biochemist
在 consultingbiochemist.com 的电子邮件经过验证 - 首页
标题
引用次数
引用次数
年份
Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation
F Wang, J Travins, B DeLaBarre, V Penard-Lacronique, S Schalm, ...
Science 340 (6132), 622-626, 2013
9532013
Complete structure of p97/valosin-containing protein reveals communication between nucleotide domains
B DeLaBarre, AT Brunger
Nature Structural & Molecular Biology 10 (10), 856-863, 2003
4622003
AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations
K Yen, J Travins, F Wang, MD David, E Artin, K Straley, A Padyana, ...
Cancer discovery 7 (5), 478-493, 2017
4382017
Central pore residues mediate the p97/VCP activity required for ERAD
B DeLaBarre, JC Christianson, RR Kopito, AT Brunger
Molecular cell 22 (4), 451-462, 2006
2682006
Conformational changes of the multifunction p97 AAA ATPase during its ATPase cycle
I Rouiller, B DeLaBarre, AP May, WI Weis, AT Brunger, RA Milligan, ...
Nature structural biology 9 (12), 950-957, 2002
2532002
Nucleotide dependent motion and mechanism of action of p97/VCP
B DeLaBarre, AT Brunger
Journal of molecular biology 347 (2), 437-452, 2005
2082005
Small molecule activation of PKM2 in cancer cells induces serine auxotrophy
C Kung, J Hixon, S Choe, K Marks, S Gross, E Murphy, B DeLaBarre, ...
Chemistry & biology 19 (9), 1187-1198, 2012
1952012
Full-length human glutaminase in complex with an allosteric inhibitor
B DeLaBarre, S Gross, C Fang, Y Gao, A Jha, F Jiang, J Song J, W Wei, ...
Biochemistry 50 (50), 10764-10770, 2011
1672011
An allosteric mechanism for potent inhibition of human ATP-citrate lyase
J Wei, S Leit, J Kuai, E Therrien, S Rafi, HJ Harwood Jr, B DeLaBarre, ...
Nature 568 (7753), 566-570, 2019
1292019
AG-348 enhances pyruvate kinase activity in red blood cells from patients with pyruvate kinase deficiency
C Kung, J Hixon, PA Kosinski, G Cianchetta, G Histen, Y Chen, C Hill, ...
Blood, The Journal of the American Society of Hematology 130 (11), 1347-1356, 2017
1082017
NSF and p97/VCP: similar at first, different at last
AT Brunger, B DeLaBarre
FEBS letters 555 (1), 126-133, 2003
1002003
Biochemical, cellular, and biophysical characterization of a potent inhibitor of mutant isocitrate dehydrogenase IDH1
MI Davis, S Gross, M Shen, KS Straley, R Pragani, WA Lea, ...
Journal of Biological Chemistry 289 (20), 13717-13725, 2014
972014
Considerations for the refinement of low-resolution crystal structures
B DeLaBarre, AT Brunger
Acta Crystallographica Section D: Biological Crystallography 62 (8), 923-932, 2006
972006
Action at a distance: allostery and the development of drugs to target cancer cell metabolism
B DeLaBarre, J Hurov, G Cianchetta, S Murray, L Dang
Chemistry & biology 21 (9), 1143-1161, 2014
922014
Therapeutically active compounds and their methods of use
G Cianchetta, B Delabarre, J Popovici-Muller, FG Salituro, JO Saunders, ...
US Patent 9,732,062, 2017
732017
X-ray structure determination at low resolution
AT Brunger, B DeLaBarre, JM Davies, WI Weis
Acta Crystallographica Section D: Biological Crystallography 65 (2), 128-133, 2009
632009
Crystal structures of homoserine dehydrogenase suggest a novel catalytic mechanism for oxidoreductases
B DeLaBarre, PR Thompson, GD Wright, AM Berghuis
nature structural biology 7 (3), 238-244, 2000
622000
Discovery of AG-270, a First-in-Class Oral MAT2A Inhibitor for the Treatment of Tumors with Homozygous MTAP Deletion
Z Konteatis, J Travins, S Gross, K Marjon, A Barnett, E Mandley, B Nicolay, ...
Journal of Medicinal Chemistry 64 (8), 4430-4449, 2021
532021
Mesenchymal phenotype predisposes lung cancer cells to impaired proliferation and redox stress in response to glutaminase inhibition
DB Ulanet, K Couto, A Jha, S Choe, A Wang, HK Woo, M Steadman, ...
PLoS One 9 (12), e115144, 2014
532014
Bi-specific fusion proteins
U Nielsen, T Wickham, B Schoeberl, B Harms, B Linggi, M Onsum, ...
US Patent 9,238,080, 2016
402016
系统目前无法执行此操作,请稍后再试。
文章 1–20